207 related articles for article (PubMed ID: 8053490)
21. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
22. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
24. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
26. bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation.
Morales-Ducret CR; van de Rijn M; Smoller BR
Arch Dermatol; 1995 Aug; 131(8):915-8. PubMed ID: 7632063
[TBL] [Abstract][Full Text] [Related]
27. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
28. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin.
Saitoh K; Takahashi H; Sawada N; Parsons PG
J Pathol; 1994 Nov; 174(3):191-9. PubMed ID: 7823252
[TBL] [Abstract][Full Text] [Related]
29. FGF-2 blocks TGF-beta1-mediated suppression of Bcl-2 in normal melanocytes.
von Willebrand M; Köhler K; Alanko T; Laiho M; Saksela O
Exp Dermatol; 2005 Mar; 14(3):202-8. PubMed ID: 15740593
[TBL] [Abstract][Full Text] [Related]
30. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics.
Barnhill RL
Clin Plast Surg; 2000 Jul; 27(3):331-60, viii. PubMed ID: 10941557
[TBL] [Abstract][Full Text] [Related]
31. Ultraviolet A and B differently induce intracellular protein expression in human skin melanocytes--a speculation of separate pathways in initiation of melanoma.
Zhang H; Rosdahl I
Carcinogenesis; 2003 Dec; 24(12):1929-34. PubMed ID: 14514652
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
34. S100-negative junctional melanocytic proliferations.
Wilson ML; Hossler EW; Ferringer TC; Elston DM
Am J Dermatopathol; 2011 May; 33(3):327-9. PubMed ID: 20940618
[No Abstract] [Full Text] [Related]
35. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
36. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
[TBL] [Abstract][Full Text] [Related]
37. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 27 is expressed in normal and malignant human melanocytes in vivo.
Kang SH; Fung MA; Gandour-Edwards R; Reilly D; Dizon T; Grahn J; Isseroff RR
J Cutan Pathol; 2004 Nov; 31(10):665-71. PubMed ID: 15491326
[TBL] [Abstract][Full Text] [Related]
40. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
